Priority 2 from the Juvenile Idiopathic Arthritis (Netherlands) PSP
|UNCERTAINTY: What is the best treatment plan for each individual patient? (e.g. start a biological directly, which one, what to do when the first one does not work, and how can medication best be tapered off?) (JLA PSP Priority 2)|
|JLA question ID||0094/2|
|Explanatory note||This question is about precision medicine, and asks what treatment is effective for which patient. Importantly, it also asks about tapering off medication when the disease is in remission.|
Systematic review - Davies et al. Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes. A systematic review. Semin Arthritis Rheum 2017;46:584-593.
Systematic review-based + expert panel - Ringold et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis and enthesitis. Arthritis Rheumatol 2019;71:846.
|Health Research Classification System category||Inflammatory and immune system|
|Extra information provided by this PSP|
|Original uncertainty examples||See data spreadsheet on JLA website|
|Submitted by||See data spreadsheet on JLA website|
|PSP unique ID||0094|
|PSP name||Juvenile Idiopathic Arthritis (Netherlands)|
|Total number of uncertainties identified by this PSP.||53 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)|
|Date of priority setting workshop||7 February 2020|